Hearing loss after cisplatin-based chemotherapy: Patient-reported outcomes versus audiometric assessments.

Authors

null

Shirin Ardeshirrouhanifard

Indiana University School of Medicine, Indianapolis, IN

Shirin Ardeshirrouhanifard , Sophie Fosså , Robert A Huddart , Patrick O. Monahan , Chunkit Fung , Yiqing Song , M. Eileen Dolan , Darren R. Feldman , Robert James Hamilton , David J. Vaughn , Neil E. Martin , Christian K. Kollmannsberger , Paul C Dinh Jr., Lifang Hou , Yinan Zheng , Lawrence Einhorn , Robert D. Frisina , Lois B. Travis

Organizations

Indiana University School of Medicine, Indianapolis, IN, National Advisory Unit on Late Effects After Cancer Treatment, Oslo, Norway, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, J.P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, Indiana University Richard M Fairbanks School of Public Health, Indianapolis, IN, Department of Medicine, University of Chicago, Chicago, IL, Memorial Sloan Kettering Cancer Center, New York, NY, Division of Urologic Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Department of Medicine, University of Pennsylvania, Philadelphia, PA, Dana Farber Cancer Institute, Boston, MA, Division of Medical Oncology, University of British Columbia, Vancouver, BC, Canada, Feinberg School of Medicine, Northwestern University, Chicago, IL, Northwestern University, Chicago, IL, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, Departments of Medical Engineering and Communication Sciences and Disorders, Global Center for Hearing and Speech Research, University of South Florida, Tampa, FL

Research Funding

U.S. National Institutes of Health
U.S. National Institutes of Health

Background: Although pure-tone audiometry is the gold standard to evaluate hearing loss (HL), patient-reported outcomes are practically more time and cost effective. However, no data exist on factors associated with discrepancies between patient-reported and audiometrically-defined HL in adult-onset cancer survivors after cisplatin-based chemotherapy (CBCT); and few comprehensive assessments of factors associated with audiometrically-defined HL have been conducted. Methods: A total of 1,410 testicular cancer survivors (TCS) ≥6 months post-CBCT completed comprehensive audiometric assessments (0.25-12 kHz) and detailed questionnaires of sociodemographic, clinical, and health behaviors. Audiometrically-defined HL severity was defined using American Speech-Language-Hearing Association (ASHA) criteria. Multivariable multinomial logistic regression identified factors associated with discrepancies (overestimation and underestimation vs. concordance), between patient-reported and audiometrically-defined HL and multivariable ordinal logistic regression evaluated factors associated with the HL severity. Results: Overall, 34.8% of TCS self-reported HL, while 77.8% had audiometrically-defined HL. Among TCS without tinnitus, those with audiometrically-defined HL at only extended high frequencies (EHFs) (10-12 kHz) (17.8%) or at both EHFs and standard frequencies (0.25-8 kHz) (23.4%) were significantly more likely to self-report HL than those with no audiometrically-defined HL (8.1%) (OR = 2.48; 95%CI, 1.31-4.68 and OR = 3.49; 95%CL,1.89-6.44, respectively). Older age (OR = 1.09; P< 0.0001), absence of prior noise exposure (OR = 1.40; P= 0.02), and mixed/conductive HL (OR = 2.01; P= 0.0007) were associated with greater underestimation of audiometrically-defined HL severity. Hearing aid use (OR = 0.18; P= 0.003) and higher education (P= 0.004) were associated with less underestimation of audiometrically-defined HL severity, while tinnitus was associated with greater overestimation (P< 0.0001). Older age (OR = 1.13; P< 0.0001), cumulative cisplatin dose ( > 300 mg/m2, OR = 1.47; P= 0.0001), and hypertension (OR = 1.80; P= 0.0007) were associated with greater ASHA-defined HL severity, whereas post-graduate education (OR = 0.58; P= 0.005) was associated with less severe HL. Conclusions: Discrepancies between patient-reported and audiometrically-defined HL after CBCT are associated with several factors including age, education, tinnitus, prior noise exposure, use of hearing aids, and conductive HL. Understanding these factors will help clinicians to better interpret self-reported HL as a surrogate for audiometric assessments. For survivors who self-report HL, but have normal audiometric findings at standard frequencies, referral to an audiologist for additional testing and inclusion of EHFs in audiometric assessments, should be considered.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Germ Cell/Testicular Cancer

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 5016)

DOI

10.1200/JCO.2021.39.15_suppl.5016

Abstract #

5016

Abstract Disclosures

Similar Abstracts

First Author: Megan Shuey

First Author: Shirin Ardeshirrouhanifard

Abstract

2024 ASCO Genitourinary Cancers Symposium

Longitudinal assessment of cognitive functioning in testicular germ cell tumor survivors.

First Author: Zuzana Orszaghova